openPR Logo
Press release

Persistent Epithelial Defect Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034

10-23-2024 06:32 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Persistent Epithelial Defect Market

Persistent Epithelial Defect Market

The Persistent Epithelial Defect market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Dompe Farmaceutici, Amber Ophthalmics, Kala Bio, Kiora Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., Amber Ophthalmics, Inc., Noveome Biotherapeutics, formerly Stemnion, Amber Ophthalmics, Inc.

[Nevada, United States] - DelveInsight's "Persistent Epithelial Defect Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Persistent Epithelial Defect, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Persistent Epithelial Defect Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/sample-request/persistent-epithelial-defect-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Persistent Epithelial Defect Market Report:
• The Persistent Epithelial Defect market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
• In September, 2024: Combangio, Inc announced that the objective of their study is to investigate the safety and efficacy of KPI-012 compared to vehicle in participants who have a documented clinical diagnosis of PCED.
• In August, 2024: Amber Ophthalmics, Inc. announced that their study is to evaluate the safety and efficacy of NEXAGON® (lufepirsen ophthalmic gel) (NEXAGON) in subjects with persistent corneal epithelial defects (PCED). The objectives of the study are to evaluate the safety and efficacy of NEXAGON in this population.
• In April, 2024: Kiora Pharmaceuticals, Inc. announced that the objective of their study is to evaluate the safety and effectiveness of topical KIO-201 in patients with persistent corneal epithelial defects (PED). KIO-201 will be administered six (6) times per day while awake for 4 weeks.
• As per DelveInsight analysis, the total Incident Cases of PCED in the 7MM were found to be approximately 242,647 cases in 2021, which are expected to increase by 2034.
• According to estimates based on DelveInsight's analysis, the US accounted for nearly 42.7% of the total Incident Cases of PCED in the 7MM in the year 2021, which are expected to increase further by 2034.
• According to estimates based on DelveInsight's epidemiology model for PCED, the gender distribution of the disease suggests a male predominance across the 7MM, with approximately 62,105 male and 41,403 female cases in the US in 2021.
• Key Persistent Epithelial Defect Companies are as follows: Dompe Farmaceutici, Amber Ophthalmics, Kala Bio, Kiora Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., Amber Ophthalmics, Inc., Noveome Biotherapeutics, formerly Stemnion, Amber Ophthalmics, Inc.
• Key Persistent Epithelial Defect Therapies are as follow: OXERVATE, NEXAGON (Lufepirsen ophthalmic gel), KPI-012, KIO-201, DE-105, lufepirsen, ST266, Nexagon
• Launching multiple stage Persistent Epithelial Defect pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Persistent Epithelial Defect market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/report-store/persistent-epithelial-defect-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Persistent Epithelial Defect Overview:
Corneal epithelial defects are some of the most common ocular pathologies that present to ophthalmologists. An acute epithelial lesion usually heals over a 7-14 day time frame. These defects are persistent or non-healing when there is no re-epithelialization despite standard therapy. The normal corneal healing process gets disrupted due to defective epithelial adhesion, limbal stem cell deficiency, surface trauma, medications, infections, and several other etiologies.

Persistent Epithelial Defect Epidemiology Segmentation:
The Persistent Epithelial Defect market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Persistent Epithelial Defect Total Incident Cases
• Persistent Epithelial Defect Gender-specific Incident Cases
• Persistent Epithelial Defect Etiology-specific Incident Cases

For more information about Persistent Epithelial Defect companies working in the treatment market, visit https://www.delveinsight.com/sample-request/persistent-epithelial-defect-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Persistent Epithelial Defect Market Insights
Persistent Epithelial Defect (PED) is a chronic, non-healing corneal condition characterized by the failure of the corneal epithelium to re-epithelialize despite appropriate treatment. It occurs due to various underlying causes, such as neurotrophic keratopathy, corneal injury, infection, or post-surgical complications. Left untreated, PED can lead to severe complications, including corneal scarring, infections, and even vision loss. The increasing prevalence of eye diseases, especially in aging populations and patients with diabetes, is driving interest in new treatment approaches for PED.

Persistent Epithelial Defect Drugs Uptake
• Oxervate is a recombinant human nerve growth factor (NGF) eye drop that has gained approval in the treatment of neurotrophic keratitis, one of the causes of PED. It stimulates corneal nerve regeneration and enhances epithelial healing.
• ASEDs are prepared from the patient's own blood serum, which contains growth factors and proteins that promote corneal healing. These drops have been used successfully for many years, especially in cases of neurotrophic ulcers and severe dry eye, to enhance epithelial regeneration.
• Amniotic membrane transplantation is an effective option for patients with PED who do not respond to conventional therapy. The Prokera® amniotic membrane graft is a commercially available product that promotes epithelial healing and reduces inflammation.
• RGTA-based treatments, such as Cacicol®, are designed to restore the extracellular matrix of the cornea, which is crucial for epithelial healing.
• Stem cell-based therapies, particularly limbal stem cell transplantation, have emerged as potential curative treatments for PED.

Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/sample-request/persistent-epithelial-defect-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Persistent Epithelial Defect Therapies and Key Companies:
• OXERVATE: Dompe Farmaceutici
• NEXAGON (Lufepirsen ophthalmic gel): Amber Ophthalmics
• KPI-012: Kala Bio
• KIO-201: Kiora Pharmaceuticals, Inc.
• DE-105: Santen Pharmaceutical Co., Ltd.
• lufepirsen: Amber Ophthalmics, Inc.
• ST266: Noveome Biotherapeutics, formerly Stemnion
• Nexagon: Amber Ophthalmics, Inc.

Persistent Epithelial Defect Epidemiology:
The epidemiology section provides insights into historical, current, and forecasted trends in the seven major countries (7MM) from 2020 to 2034. It explores various studies and opinions to recognize the causes of current and forecasted trends. The segmentation includes total prevalence, severity-based prevalence, gender-specific prevalence, and diagnosed cases of episodic and chronic Persistent Epithelial Defect.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/persistent-epithelial-defect-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Persistent Epithelial Defect Market Drivers:
• Aging Population and Growing Prevalence of Diabetes
• Advancements in Ophthalmology
• Increased Awareness and Diagnosis
• Development of Biological and Regenerative Therapies

Persistent Epithelial Defect Market Barriers:
• High Cost of Biologic and Regenerative Therapies
• Limited Availability of Autologous Serum Eye Drop
• Regulatory Hurdles
• Lack of Standardized Treatment Guidelines

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/persistent-epithelial-defect-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Persistent Epithelial Defect Market Report:
• Study Period: 2020-2034
• Coverage: 7MM (The United States, EU5, and Japan)
• Key Persistent Epithelial Defect Companies: Dompe Farmaceutici, Amber Ophthalmics, Kala Bio, Kiora Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., Amber Ophthalmics, Inc., Noveome Biotherapeutics, formerly Stemnion, Amber Ophthalmics, Inc.
• Key Persistent Epithelial Defect Therapies: OXERVATE, NEXAGON (Lufepirsen ophthalmic gel), KPI-012, KIO-201, DE-105, lufepirsen, ST266, Nexagon
• Persistent Epithelial Defect Therapeutic Assessment: Current marketed and emerging therapies
• Persistent Epithelial Defect Market Dynamics: Persistent Epithelial Defect Market drivers and Persistent Epithelial Defect barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Persistent Epithelial Defect Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Persistent Epithelial Defect market outlook, drug uptake, treatment scenario, and epidemiology trends, https://www.delveinsight.com/sample-request/persistent-epithelial-defect-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1 Key Insights
2 Report Introduction
3 Persistent Corneal Epithelial Defects Market Overview at a Glance
4 Epidemiology and Market Methodology
5 Executive Summary
6 Key Events
7 Disease Background and Overview
8 Epidemiology and Patient Population
9 Patient Journey
10 Marketed Drugs
11 Emerging Drugs
12 Persistent Corneal Epithelial Defects: Seven Major Market Analysis
13 KOL Views
14 SWOT Analysis
15 Unmet Needs
16 Market Access and Reimbursement
17 Appendix
18 DelveInsight Capabilities
19 Disclaimer
20 About DelveInsight

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Persistent Epithelial Defect Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034 here

News-ID: 3707083 • Views:

More Releases from DelveInsight Business Research LLP

Genital Warts Pipeline Insights Report 2025 | DelveInsight
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market

All 5 Releases


More Releases for Persistent

Evolving Market Trends In The Advanced Persistent Threat Protection Industry: In …
The Advanced Persistent Threat Protection Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Expected Advanced Persistent Threat Protection Market Size During the Forecast Period? The market size for advanced persistent threat protection has seen a substantial increase in the recent past. It is
Advanced Persistent Threat Protection Market Size and Forecast
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Advanced Persistent Threat Protection Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion. The Advanced Persistent Threat (APT) Protection market is experiencing significant growth due to the increasing frequency and sophistication of cyberattacks. APTs are long-term,
Decentralized Identity Systems Market Dynamics and Demand A Deep Dive into Trend …
The Decentralized Identity Systems Market is an emerging and transformative sector within the blockchain and digital identity industries, offering a secure and user-centric approach to managing identity information. Decentralized identity systems empower individuals to have more control over their personal data and digital identities, reducing reliance on centralized entities for identity verification. These systems utilize blockchain technology and cryptography to provide secure, privacy-enhancing, and interoperable solutions for identity management. As
Global Advanced Persistent Threat Protection Market
The data examined by GME predicted that by 2026, the Global Advanced Persistent Threat Protection Market would grow with a CAGR value of 19.5 percent. External threats are constantly on the lookout for opportunities to hack security networks and obtain access to sensitive data. Hence, with the rising cases of cyber security thefts or crime will help propel the market from 2021 to 2026. Moreover the market is projected to
Pyrometer Market Expansion to be Persistent During 2028
Pyrometer Market – Notable Developments In April 2019, AMETEK Land revealed its enhanced SPOT infrared pyrometer software packages, SPOTPro and SPOTViewer. The newly launched pyrometer packages are aimed at giving users a better understand of the performance of various processes and aid them in realizing industry 4.0 connectivity. In December 2018, Extech announced launch of a ruggedized, dual-laser infrared (IR) thermometer named IR320, which is designed to perform rough and tough jobs
DevSecOps Market Expansion to be Persistent during 2023
Overview: In the recent times, a new trend is gaining popularity in the software development life cycle called DevSecOps. This technology bridges the gap between development, operations, and security teams to speed up the software development process through collaboration and communication among the teams. The goal of DevOps is to give more ownership to the development team for developing and monitoring applications. Security plays a key role by providing high-end security